Quick Answer
Grace Therapeutics, Inc. reported Operating Income of -$16.68 million for fiscal year 2025.
Grace Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$16.68M | -29.8% |
| 2024 | -$12.85M | +75.4% |
| 2023 | -$52.16M | -234.6% |
| 2022 | -$15.59M | +5.1% |
| 2021 | -$16.42M | +32.8% |
| 2020 | -$24.44M | +29.0% |
| 2019 | -$34.41M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$2.45M | +33.9% | +3.2% |
| September 30, 2025 | -$2.53M | +47.7% | +18.2% |
| June 30, 2025 | -$3.09M | +37.7% | +16.6% |
| December 31, 2024 | -$3.70M | -21.7% | +23.3% |
| September 30, 2024 | -$4.83M | -130.9% | +2.7% |
| June 30, 2024 | -$4.96M | -11.4% | -63.1% |
| December 31, 2023 | -$3.04M | +28.3% | -45.5% |
| September 30, 2023 | -$2.09M | +59.0% | +53.0% |
- Grace Therapeutics, Inc. showed a decrease of -29.8% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Grace Therapeutics, Inc.’s operating income has grown by 51.5% (from -$34.41 million to -$16.68 million).
- The most recent figure is from Grace Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: